标题
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
作者
关键词
-
出版物
Biomed Research International
Volume 2019, Issue -, Pages 1-17
出版商
Hindawi Limited
发表日期
2019-07-19
DOI
10.1155/2019/8142368
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus
- (2018) Tineke Kraaij et al. JOURNAL OF AUTOIMMUNITY
- Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab
- (2018) Sherry Masoud et al. RHEUMATOLOGY
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
- (2018) Joan T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- Adverse Reactions to Biologic Therapy
- (2017) Sheenal V. Patel et al. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
- Biotherapies in systemic lupus erythematosus: New targets
- (2017) Estibaliz Lazaro et al. JOINT BONE SPINE
- Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials
- (2017) Y H Lee et al. LUPUS
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis
- (2017) Julien Hogan et al. PEDIATRIC NEPHROLOGY
- Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
- (2017) Venkat Reddy et al. RHEUMATOLOGY
- Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence
- (2017) Savino Sciascia et al. RHEUMATOLOGY INTERNATIONAL
- Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
- (2017) Aleksander Lenert et al. Drug Design Development and Therapy
- Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
- (2017) Megan E. B. Clowse et al. Arthritis & Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
- (2016) Munther Khamashta et al. ANNALS OF THE RHEUMATIC DISEASES
- Restoring regulation – IL-2 therapy in systemic lupus erythematosus
- (2016) Jens Y. Humrich et al. Expert Review of Clinical Immunology
- A critical review of clinical trials in systemic lupus erythematosus
- (2016) M A Mahieu et al. LUPUS
- Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus
- (2016) Theofanis Karageorgas et al. RHEUMATOLOGY
- Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
- (2016) D. J. Wallace et al. ARTHRITIS CARE & RESEARCH
- Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
- (2016) Caroline Gordon et al. Arthritis & Rheumatology
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
- (2016) Brad H. Rovin et al. Arthritis & Rheumatology
- Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) J T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
- (2015) Kenneth C Kalunian et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) D A Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus
- (2015) Thomas Dörner et al. AUTOIMMUNITY REVIEWS
- Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
- (2015) J. S. Hui-Yuen et al. JOURNAL OF RHEUMATOLOGY
- Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
- (2015) Li Peng et al. mAbs
- A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
- (2014) R A Furie et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
- (2014) David Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Emerging biological therapies for systemic lupus erythematosus
- (2014) Chi Chiu Mok EXPERT OPINION ON EMERGING DRUGS
- Current role of rituximab in systemic lupus erythematosus
- (2014) Chi Chiu Mok International Journal of Rheumatic Diseases
- Type I Interferon in the Pathogenesis of Lupus
- (2014) M. K. Crow JOURNAL OF IMMUNOLOGY
- When biologics should be used in systemic lupus erythematosus?
- (2014) Jacques-Eric Gottenberg et al. PRESSE MEDICALE
- Ofatumumab: a novel treatment for severe systemic lupus erythematosus
- (2014) C. C. Thornton et al. RHEUMATOLOGY
- Belimumab for the Treatment of Systemic Lupus Erythematosus (Sle) In Greece: A Cost-Effectiveness and Cost-Utility Analysis
- (2014) K. Athanasakis et al. VALUE IN HEALTH
- Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
- (2014) Maria Lucia Specchia et al. Biomed Research International
- Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
- (2014) Arthritis & Rheumatology
- Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
- (2013) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
- (2013) Daniel J Wallace et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials
- (2013) David Wofsy et al. ARTHRITIS AND RHEUMATISM
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
- (2013) Eduardo F. Mysler et al. ARTHRITIS AND RHEUMATISM
- Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study
- (2013) Michelle Petri et al. ARTHRITIS AND RHEUMATISM
- Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab
- (2013) E. A. Rossi et al. BLOOD
- Targeting the complement system in systemic lupus erythematosus and other diseases
- (2013) Maria-Louise Barilla-LaBarca et al. CLINICAL IMMUNOLOGY
- Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)
- (2013) M Witt et al. LUPUS
- Epratuzumab for Systemic Lupus Erythematosus
- (2013) DJ Wallace et al. LUPUS
- Belimumab for Systemic Lupus Erythematosus
- (2013) Bevra Hannahs Hahn NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study
- (2013) Richard Furie et al. Arthritis & Rheumatology
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
- (2012) Susan Manzi et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study
- (2012) Jacqueline M. McBride et al. ARTHRITIS AND RHEUMATISM
- Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
- (2012) William Stohl et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha
- (2012) Eben I. Lichtman et al. CLINICAL IMMUNOLOGY
- Abatacept for systemic lupus erythematosus: the outlook
- (2012) Chi Chiu Mok EXPERT OPINION ON BIOLOGICAL THERAPY
- Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
- (2012) A Fernández-Nebro et al. LUPUS
- Optimization of current and future therapy for autoimmune diseases
- (2012) Lawrence Steinman et al. NATURE MEDICINE
- Safety profile and clinical activity of sifalimumab, a fully human anti-interferon monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
- (2011) J. T. Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- B cell biomarkers of rituximab responses in systemic lupus erythematosus
- (2011) Edward M. Vital et al. ARTHRITIS AND RHEUMATISM
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
- (2011) Cándido Díaz-Lagares et al. AUTOIMMUNITY REVIEWS
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside
- (2011) William Stohl et al. CURRENT OPINION IN RHEUMATOLOGY
- Type I Interferon and Systemic Lupus Erythematosus
- (2011) Keith B. Elkon et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- The type I interferon system in the development of lupus
- (2011) Lars Rönnblom et al. SEMINARS IN IMMUNOLOGY
- EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
- (2010) G. K. Bertsias et al. ANNALS OF THE RHEUMATIC DISEASES
- Unanswered questions in evaluating rituximab efficacy: Comment on the article by Merrill et al
- (2010) Lidia Rudnicka et al. ARTHRITIS AND RHEUMATISM
- The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
- (2010) J. T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
- (2010) J.-E. Gottenberg et al. ARTHRITIS AND RHEUMATISM
- Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry
- (2010) Benjamin Terrier et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study
- (2009) Jason W. Bauer et al. ARTHRITIS AND RHEUMATISM
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
- (2009) Daniel J. Wallace et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Abetimus sodium: a medication for the prevention of lupus nephritis flares
- (2009) Diane M Horowitz et al. EXPERT OPINION ON PHARMACOTHERAPY
- A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells
- (2009) Aixin Yu et al. IMMUNITY
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
- (2009) Michael P. Cancro et al. JOURNAL OF CLINICAL INVESTIGATION
- CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn-/- Mice
- (2009) S. A. Oracki et al. JOURNAL OF IMMUNOLOGY
- Efficacy and safety of infliximab in active SLE: a pilot study
- (2009) SS Uppal et al. LUPUS
- Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
- (2009) M Ramos-Casals et al. LUPUS
- Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
- (2008) D Albert et al. ANNALS OF THE RHEUMATIC DISEASES
- Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial
- (2008) Mario H. Cardiel et al. ARTHRITIS AND RHEUMATISM
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
- (2008) Richard Furie et al. ARTHRITIS RESEARCH & THERAPY
- Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus
- (2007) M Nikpour et al. ANNALS OF THE RHEUMATIC DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now